- Reaction score
- 1,739
Rabies, a deadly viral disease, has long been a threat to human lives, especially in regions like Africa and Asia, where it claims nearly 60,000 lives annually. Until now, there has been no reliable treatment for symptomatic rabies once the virus invades the central nervous system (CNS). However, recent research has uncovered a potential game-changer in the fight against this relentless killer: the monoclonal antibody F11.
The rabies virus becomes fatal once it reaches the central nervous system, causing severe symptoms. Conventional immunotherapies have primarily focused on preventing CNS infection during the early, pre-symptomatic stages of the disease. However, the groundbreaking study we’re discussing here evaluates the therapeutic potential of F11, a human monoclonal antibody, in treating established lyssavirus infections.
Rabies, though rare in industrialized countries, continues to pose a significant threat in the developing world, especially among young individuals. The World Health Organization has set a goal of eradicating rabies by 2030, but progress has been slow. Therefore, there is an urgent need for cost-effective and easily administrable therapies.
The discovery that peripherally administered monoclonal antibody therapy, like F11, can promote survival and reverse disease signs in lyssavirus-infected animals offers a glimmer of hope. This breakthrough suggests that a similar therapy for humans could be developed, meeting the criteria for effective rabies treatment in resource-constrained healthcare facilities.
The rabies virus becomes fatal once it reaches the central nervous system, causing severe symptoms. Conventional immunotherapies have primarily focused on preventing CNS infection during the early, pre-symptomatic stages of the disease. However, the groundbreaking study we’re discussing here evaluates the therapeutic potential of F11, a human monoclonal antibody, in treating established lyssavirus infections.
Rabies, though rare in industrialized countries, continues to pose a significant threat in the developing world, especially among young individuals. The World Health Organization has set a goal of eradicating rabies by 2030, but progress has been slow. Therefore, there is an urgent need for cost-effective and easily administrable therapies.
The discovery that peripherally administered monoclonal antibody therapy, like F11, can promote survival and reverse disease signs in lyssavirus-infected animals offers a glimmer of hope. This breakthrough suggests that a similar therapy for humans could be developed, meeting the criteria for effective rabies treatment in resource-constrained healthcare facilities.
Promising Breakthrough: Monoclonal Antibody F11 Offers Hope for Rabies Treatment | TrendinTech
Rabies, a deadly viral disease, has long been a threat to human lives, especially in regions like Africa and Asia, where it claims nearly 60,000 lives annually. Until now, there has been no reliable treatment for symptomatic rabies once the virus invades the central nervous system (CNS)...
trendintech.com
